TransThera Sciences (Nanjing) (2617.HK) Earnings Analysis
TransThera Sciences (Nanjing) (2617.HK) has no confirmed upcoming earnings date. Trailing P/E -9.13.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2617.HK next report earnings?
No confirmed upcoming earnings date is currently scheduled for 2617.HK. This page updates as the calendar is published.
2617.HK earnings history — beats and misses
No reported earnings history is available for this symbol in our dataset.
2617.HK valuation and analyst view
| Trailing P/E | -9.13 |
|---|---|
| Trailing EPS | -0.73306 HKD |
| Price / book | 8.88 |
| Dividend yield | 0.00% |
| Market cap | 4.33B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is TransThera Sciences (Nanjing) (2617.HK)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 2617.HK. This page updates as the calendar is published.
What is 2617.HK's current P/E ratio and EPS?
2617.HK trades at a trailing P/E of -9.13 on trailing EPS of -0.7330593150702917 HKD.
What do analysts rate 2617.HK?
2617.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.